Q-omics provides the consensus-scored LILRB5 profile across patient tissues and cancer cell-line models. LILRB5 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, LILRB5 is differentially expressed in 12, with the highest sampling consensus in COAD. Additionally, LILRB5 RNA expression shows 19,573 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight UVM, COAD, and LSCC as cancer lineages where LILRB5 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LILRB5 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LILRB5 survival associations across molecular data types. LILRB5 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (8) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LILRB5 RNA expression–survival associations across cancer types. High LILRB5 expression shows unfavorable associations in UVM and BRCA, but favorable associations in SKCM, LGG, LUAD and KIRC. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .005). Together, the overview and detailed table identify UVM as the clearest survival context for LILRB5 RNA expression.
This table summarizes LILRB5 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 8. The strongest signals are observed in KIRC for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for LILRB5. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LILRB5 shows lower tumor expression in COAD, BLCA, LIHC, BRCA and LUSC and higher tumor expression in KIRC. The COAD box plot shows higher LILRB5 RNA expression in normal versus tumor tissue (log2 FC = −2.178, t-test p < 0.001).
This table shows molecular features associated with LILRB5 in patient tissues and cancer cell lines. In patient samples, LILRB5 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, LILRB5 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and LARGE_INTESTINE.
